A Phase 1/2 study of BMX-001 in Anal Cancer
Active, Not Recruiting Phase 1,Phase 2 NCT03386500
Study Description
A study to evaluate the safety and effectiveness of BMX-001, a radioprotective drug, in combination with radiation therapy and chemotherapy for newly diagnosed Anal Squamous Cell Carcinoma
Study Details
- Registry ID:
- NCT03386500
- Conditions:
- Anal Cancer, Squamous Cell Carcinoma, Radiation Exposure
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 19–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
University of Nebraska Medical Center
Omaha, Nebraska, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.